Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.82 |
| ▸ | F2 | P00734 | 4/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253401 | 0.94 | F10 (0.78) | F10F2 | |
| SCHEMBL12833335 | 0.94 | F10 (0.77) | F10F2 | |
| SCHEMBL1252828 | 0.93 | F10 (0.76) | F10F2 | |
| SCHEMBL13631342 | 0.91 | F10 (0.82) | F10F2 | |
| SCHEMBL3204841 | 0.90 | F10 (1.00) | F10F2 | |
| SCHEMBL3470219 | 0.90 | F10 (1.00) | F10F2 | |
| SCHEMBL3188764 | 0.90 | F10 (1.00) | F10F2 | |
| SCHEMBL3188759 | 0.90 | F10 (1.00) | F10F2 | |
| SCHEMBL12036200 | 0.90 | F10 (1.00) | F10F2 | |
| Hydrochloric Acid SCHEMBL2943628 | 0.90 | F10 (0.99) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | F10 152/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.